AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Baxter International Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

IonQ (NYSE: IONQ) has launched a $1.0 billion capital raise through a mixed offering of 14.17 million new common shares at $55.49 and 39.9 million warrants (36.0 million Series A at a $99.88 strike and 3.86 million pre-funded warrants at $0.0001). The gross proceeds total $1.0 billion and net proceeds, after $20.0 million in underwriting fees and $1.5 million in expenses, are projected at $978.5 million.

The financing will lift total shares outstanding from 243.1 million to 283.9 million immediately (323.8 million if all warrants are exercised), representing dilution of ~17% (or ~33%). Purchasers will experience an immediate $48.96 per-share dilution to adjusted tangible book value ($6.53 post-deal versus the $55.49 offer price). The offering price stands roughly 25% above the $44.39 closing price on 3 July 2025, signaling strong institutional demand despite dilution.

Use of proceeds: working capital, R&D, and potential strategic acquisitions/partnerships that could accelerate IonQ’s roadmap toward higher-fidelity, larger-qubit quantum systems. J.P. Morgan acts as sole underwriter; warrants will not be exchange-listed, limiting near-term liquidity.

Key risks disclosed include ongoing operating losses (accumulated deficit $716.0 million), execution challenges in scaling quantum hardware, absence of cash dividends, limited warrant liquidity, and only a 60-day lock-up on insider sales.

IonQ (NYSE: IONQ) ha avviato una raccolta di capitale da 1,0 miliardi di dollari tramite un'offerta mista di 14,17 milioni di nuove azioni ordinarie a 55,49 dollari e 39,9 milioni di warrant (36,0 milioni di Serie A con prezzo di esercizio a 99,88 dollari e 3,86 milioni di warrant prefinanziati a 0,0001 dollari). I proventi lordi ammontano a 1,0 miliardi di dollari, mentre i proventi netti, dopo 20,0 milioni di dollari di commissioni di sottoscrizione e 1,5 milioni di dollari di spese, sono stimati a 978,5 milioni di dollari.

Il finanziamento porterà il numero totale di azioni in circolazione da 243,1 milioni a 283,9 milioni immediatamente (323,8 milioni se tutti i warrant verranno esercitati), rappresentando una diluizione di circa il 17% (o circa il 33%). Gli acquirenti subiranno una diluizione immediata di 48,96 dollari per azione sul valore contabile tangibile rettificato (6,53 dollari post-operazione rispetto al prezzo di offerta di 55,49 dollari). Il prezzo di offerta è circa il 25% superiore al prezzo di chiusura del 3 luglio 2025, pari a 44,39 dollari, segnalando una forte domanda istituzionale nonostante la diluizione.

Utilizzo dei proventi: capitale circolante, ricerca e sviluppo e potenziali acquisizioni/partnership strategiche che potrebbero accelerare la roadmap di IonQ verso sistemi quantistici con qubit più numerosi e a maggiore fedeltà. J.P. Morgan agisce come unico sottoscrittore; i warrant non saranno quotati in borsa, limitando la liquidità a breve termine.

Rischi chiave evidenziati includono perdite operative continue (deficit accumulato di 716,0 milioni di dollari), difficoltà nell'esecuzione della scalabilità dell'hardware quantistico, assenza di dividendi in contanti, liquidità limitata dei warrant e solo un lock-up di 60 giorni sulle vendite da parte degli insider.

IonQ (NYSE: IONQ) ha lanzado una captación de capital de 1.0 mil millones de dólares mediante una oferta mixta de 14.17 millones de nuevas acciones ordinarias a 55.49 dólares y 39.9 millones de warrants (36.0 millones de la Serie A con precio de ejercicio a 99.88 dólares y 3.86 millones de warrants prefinanciados a 0.0001 dólares). Los ingresos brutos suman 1.0 mil millones de dólares y los ingresos netos, tras 20.0 millones en comisiones de suscripción y 1.5 millones en gastos, se proyectan en 978.5 millones de dólares.

La financiación elevará el total de acciones en circulación de 243.1 millones a 283.9 millones inmediatamente (323.8 millones si se ejercen todos los warrants), lo que representa una dilución de aproximadamente el 17% (o aproximadamente el 33%). Los compradores experimentarán una dilución inmediata de 48.96 dólares por acción en el valor contable tangible ajustado (6.53 dólares post-operación frente al precio de oferta de 55.49 dólares). El precio de la oferta está aproximadamente un 25% por encima del precio de cierre del 3 de julio de 2025, que fue de 44.39 dólares, lo que indica una fuerte demanda institucional a pesar de la dilución.

Uso de los ingresos: capital de trabajo, I+D y posibles adquisiciones/alianzas estratégicas que podrían acelerar la hoja de ruta de IonQ hacia sistemas cuánticos con más qubits y mayor fidelidad. J.P. Morgan actúa como único suscriptor; los warrants no serán listados en bolsa, limitando la liquidez a corto plazo.

Riesgos clave divulgados incluyen pérdidas operativas continuas (déficit acumulado de 716.0 millones de dólares), desafíos en la ejecución para escalar el hardware cuántico, ausencia de dividendos en efectivo, liquidez limitada de los warrants y solo un bloqueo de 60 días para ventas internas.

IonQ (NYSE: IONQ)ê°€ 10ì–� 달러 규모ì� ìžë³¸ 조달ì� 시작했습니다. ì´ëŠ” 1,417ë§� ì£¼ì˜ ì‹ ê·œ 보통주를 주당 55.49달러ì—�, 3,990ë§� ê°œì˜ ì›ŒëŸ°íŠ�(행사가 99.88달러ì� 3,600ë§� ì£� 시리ì¦� A 워런íŠ� ë°� 0.0001달러ì� ì„ ì§€ê¸� 워런íŠ� 386ë§� ì£�)ë¥� 혼합하여 발행하는 ë°©ì‹ìž…니ë‹�. ì´� 수ìµì€ 10ì–� 달러ì´ë©°, 2,000ë§� 달러ì� ì¸ìˆ˜ 수수료와 150ë§� 달러ì� 비용ì� 제외í•� 순수ìµì€ 9ì–�7,850ë§� 달러ë¡� 예ìƒë©ë‹ˆë‹�.

ì´ë²ˆ ìžê¸ˆ 조달ë¡� 발행 ì£¼ì‹ ìˆ˜ëŠ” 2ì–�4,310ë§� 주ì—ì„� 즉시 2ì–�8,390ë§� 주로 ì¦ê°€í•˜ë©°(모든 워런트가 행사ë� 경우 3ì–�2,380ë§� ì£�), í¬ì„ë¥ ì€ ì•� 17%(ë˜ëŠ” ì•� 33%)ì—� 달합니다. 투ìžìžë“¤ì€ ì¡°ì •ë� 유형 장부가ì¹� 기준으로 주당 즉시 48.96달러ì� í¬ì„ì� 경험하게 ë©ë‹ˆë‹�(거래 í›� 6.53달러, 제안가 55.49달러 대ë¹�). 제안 ê°€ê²©ì€ 2025ë…� 7ì›� 3ì� 종가 44.39달러보다 ì•� 25% ë†’ì€ ìˆ˜ì¤€ìœ¼ë¡œ, í¬ì„ì—ë„ ë¶ˆêµ¬í•˜ê³  강한 기관 수요ë¥� 나타냅니ë‹�.

ìžê¸ˆ 사용ì²�: ìš´ì „ìžë³¸, 연구개발, 그리ê³� IonQì� ê³ ì¶©ì‹¤ë„ ë°� 대규모 í비íŠ� ì–‘ìž ì‹œìŠ¤í…� 개발 ë¡œë“œë§µì„ ê°€ì†í™”í•� ìˆ� 있는 잠재ì � ì „ëžµì � ì¸ìˆ˜ ë°� 파트너십. J.P. 모건ì� ë‹¨ë… ì¸ìˆ˜ì¸ìœ¼ë¡� 참여하며, 워런트는 거래ì†� ìƒìž¥ì� ë˜ì§€ 않아 단기 유ë™ì„±ì´ 제한ë©ë‹ˆë‹�.

주요 위험 사항으로ëŠ� ì§€ì†ì ì� ì˜ì—… ì†ì‹¤(ëˆ„ì  ì ìž 7ì–�1,600ë§� 달러), ì–‘ìž í•˜ë“œì›¨ì–´ 확장 실행ì� 어려움, 현금 배당 미지ê¸�, 제한ë� 워런íŠ� 유ë™ì„�, ìž„ì› ë§¤ë„ì—� 대í•� 60ì� 잠금 기간ë§� 존재하는 ì � ë“±ì´ í¬í•¨ë©ë‹ˆë‹�.

IonQ (NYSE : IONQ) a lancé une levée de fonds d’un milliard de dollars via une offre mixte comprenant 14,17 millions de nouvelles actions ordinaires à 55,49 dollars et 39,9 millions de bons de souscription (36,0 millions de série A avec un prix d’exercice à 99,88 dollars et 3,86 millions de bons préfinancés à 0,0001 dollar). Le produit brut totalise 1,0 milliard de dollars et le produit net, après 20 millions de dollars de frais de souscription et 1,5 million de dollars de dépenses, est estimé à 978,5 millions de dollars.

Ce financement portera immédiatement le nombre total d’actions en circulation de 243,1 millions à 283,9 millions (323,8 millions si tous les bons sont exercés), ce qui représente une dilution d’environ 17 % (ou environ 33 %). Les acheteurs subiront une dilution immédiate de 48,96 dollars par action sur la valeur comptable tangible ajustée (6,53 dollars après l’opération contre le prix d’offre de 55,49 dollars). Le prix d’offre est environ 25 % supérieur au cours de clôture du 3 juillet 2025, à 44,39 dollars, indiquant une forte demande institutionnelle malgré la dilution.

Utilisation des fonds : fonds de roulement, R&D, et acquisitions/partenariats stratégiques potentiels pouvant accélérer la feuille de route d’IonQ vers des systèmes quantiques à qubits plus nombreux et de meilleure fidélité. J.P. Morgan agit en tant que seul souscripteur ; les bons ne seront pas cotés en bourse, limitant la liquidité à court terme.

Principaux risques divulgués : pertes opérationnelles continues (déficit cumulé de 716 millions de dollars), défis dans la montée en puissance du matériel quantique, absence de dividendes en espèces, liquidité limitée des bons et période de blocage de seulement 60 jours pour les ventes internes.

IonQ (NYSE: IONQ) hat eine Kapitalerhöhung in Höhe von 1,0 Milliarden US-Dollar gestartet durch ein gemischtes Angebot von 14,17 Millionen neuen Stammaktien zu 55,49 US-Dollar und 39,9 Millionen Warrants (36,0 Millionen Serie A mit einem Ausübungspreis von 99,88 US-Dollar und 3,86 Millionen vorfinanzierte Warrants zu 0,0001 US-Dollar). Die Bruttoerlöse betragen 1,0 Milliarden US-Dollar, die Nettoerlöse nach 20,0 Millionen US-Dollar Underwriting-Gebühren und 1,5 Millionen US-Dollar Ausgaben werden auf 978,5 Millionen US-Dollar ²µ±ð²õ³¦³óä³Ù³ú³Ù.

Die Finanzierung erhöht die Gesamtzahl der ausstehenden Aktien sofort von 243,1 Millionen auf 283,9 Millionen (323,8 Millionen bei Ausübung aller Warrants), was einer Verwässerung von etwa 17 % (bzw. etwa 33 %) entspricht. Käufer werden eine sofortige Verwässerung von 48,96 US-Dollar pro Aktie im bereinigten materiellen Buchwert erfahren (6,53 US-Dollar nach der Transaktion gegenüber dem Angebotspreis von 55,49 US-Dollar). Der Angebotspreis liegt etwa 25 % über dem Schlusskurs vom 3. Juli 2025 von 44,39 US-Dollar, was trotz Verwässerung auf eine starke institutionelle Nachfrage hinweist.

Verwendung der Erlöse: Betriebskapital, Forschung & Entwicklung sowie potenzielle strategische Akquisitionen/Partnerschaften, die IonQs Fahrplan zu höherwertigen, größeren Qubit-Quanten-Systemen beschleunigen könnten. J.P. Morgan fungiert als alleiniger Underwriter; die Warrants werden nicht an der Börse gehandelt, was die kurzfristige Liquidität einschränkt.

Wesentliche Risiken umfassen anhaltende operative Verluste (kumuliertes Defizit von 716,0 Millionen US-Dollar), Herausforderungen bei der Skalierung der Quantenhardware, fehlende Bardividenden, begrenzte Liquidität der Warrants sowie nur eine 60-tägige Sperrfrist für Insiderverkäufe.

Positive
  • $978.5 million in net proceeds significantly strengthens liquidity for R&D and potential acquisitions.
  • Offer priced at a 25% premium to prior close, indicating strong investor appetite.
  • No warrant listing fees and seven-year term give company flexibility without immediate dilution pressure.
  • Maintains zero financial leverage; proceeds are non-debt capital.
Negative
  • Immediate dilution of up to 33% if all warrants are exercised, lowering existing shareholder ownership.
  • Net tangible book value gap: purchasers pay $55.49 versus $6.53 pro-forma book value.
  • °ä´Ç³¾±è²¹²Ô²â’s $716 million accumulated deficit and expectation of continuing losses heighten execution risk.
  • Warrants are illiquid (no exchange listing) and Series A strike of $99.88 may never be in-the-money.

Insights

TL;DR: Raises $978.5 M cash, strengthens balance sheet, but 17-33 % dilution tempers upside.

The raise materially extends IonQ’s cash runway—vital for long-cycle quantum R&D—while keeping leverage at zero. Pricing the stock 25 % above market suggests robust demand and minimal discounting. However, investors face pronounced dilution and a tangible book value far below the offer price, limiting near-term accretion. The high $99.88 strike on Series A warrants reduces the probability of early exercise, muting potential future cash inflow. Overall, financing capacity outweighs dilution for a pre-revenue tech platform, but valuation risk remains elevated.

TL;DR: Cash influx could speed qubit scaling, M&A, and cloud expansion—strategically positive.

Quantum hardware development is capital-intensive; $978 M allows IonQ to accelerate ion-trap roadmap beyond the current 30-plus qubit class toward error-corrected architectures. Management explicitly earmarks funds for strategic acquisitions that could broaden IP (e.g., photonics, cryogenics) or secure talent. Maintaining NYSE listing without warrant overhang protects share tradability. Execution risk persists—technical milestones, customer adoption, and competitive pressure from superconducting platforms—but the enlarged war chest strengthens IonQ’s position in an emerging oligopoly.

IonQ (NYSE: IONQ) ha avviato una raccolta di capitale da 1,0 miliardi di dollari tramite un'offerta mista di 14,17 milioni di nuove azioni ordinarie a 55,49 dollari e 39,9 milioni di warrant (36,0 milioni di Serie A con prezzo di esercizio a 99,88 dollari e 3,86 milioni di warrant prefinanziati a 0,0001 dollari). I proventi lordi ammontano a 1,0 miliardi di dollari, mentre i proventi netti, dopo 20,0 milioni di dollari di commissioni di sottoscrizione e 1,5 milioni di dollari di spese, sono stimati a 978,5 milioni di dollari.

Il finanziamento porterà il numero totale di azioni in circolazione da 243,1 milioni a 283,9 milioni immediatamente (323,8 milioni se tutti i warrant verranno esercitati), rappresentando una diluizione di circa il 17% (o circa il 33%). Gli acquirenti subiranno una diluizione immediata di 48,96 dollari per azione sul valore contabile tangibile rettificato (6,53 dollari post-operazione rispetto al prezzo di offerta di 55,49 dollari). Il prezzo di offerta è circa il 25% superiore al prezzo di chiusura del 3 luglio 2025, pari a 44,39 dollari, segnalando una forte domanda istituzionale nonostante la diluizione.

Utilizzo dei proventi: capitale circolante, ricerca e sviluppo e potenziali acquisizioni/partnership strategiche che potrebbero accelerare la roadmap di IonQ verso sistemi quantistici con qubit più numerosi e a maggiore fedeltà. J.P. Morgan agisce come unico sottoscrittore; i warrant non saranno quotati in borsa, limitando la liquidità a breve termine.

Rischi chiave evidenziati includono perdite operative continue (deficit accumulato di 716,0 milioni di dollari), difficoltà nell'esecuzione della scalabilità dell'hardware quantistico, assenza di dividendi in contanti, liquidità limitata dei warrant e solo un lock-up di 60 giorni sulle vendite da parte degli insider.

IonQ (NYSE: IONQ) ha lanzado una captación de capital de 1.0 mil millones de dólares mediante una oferta mixta de 14.17 millones de nuevas acciones ordinarias a 55.49 dólares y 39.9 millones de warrants (36.0 millones de la Serie A con precio de ejercicio a 99.88 dólares y 3.86 millones de warrants prefinanciados a 0.0001 dólares). Los ingresos brutos suman 1.0 mil millones de dólares y los ingresos netos, tras 20.0 millones en comisiones de suscripción y 1.5 millones en gastos, se proyectan en 978.5 millones de dólares.

La financiación elevará el total de acciones en circulación de 243.1 millones a 283.9 millones inmediatamente (323.8 millones si se ejercen todos los warrants), lo que representa una dilución de aproximadamente el 17% (o aproximadamente el 33%). Los compradores experimentarán una dilución inmediata de 48.96 dólares por acción en el valor contable tangible ajustado (6.53 dólares post-operación frente al precio de oferta de 55.49 dólares). El precio de la oferta está aproximadamente un 25% por encima del precio de cierre del 3 de julio de 2025, que fue de 44.39 dólares, lo que indica una fuerte demanda institucional a pesar de la dilución.

Uso de los ingresos: capital de trabajo, I+D y posibles adquisiciones/alianzas estratégicas que podrían acelerar la hoja de ruta de IonQ hacia sistemas cuánticos con más qubits y mayor fidelidad. J.P. Morgan actúa como único suscriptor; los warrants no serán listados en bolsa, limitando la liquidez a corto plazo.

Riesgos clave divulgados incluyen pérdidas operativas continuas (déficit acumulado de 716.0 millones de dólares), desafíos en la ejecución para escalar el hardware cuántico, ausencia de dividendos en efectivo, liquidez limitada de los warrants y solo un bloqueo de 60 días para ventas internas.

IonQ (NYSE: IONQ)ê°€ 10ì–� 달러 규모ì� ìžë³¸ 조달ì� 시작했습니다. ì´ëŠ” 1,417ë§� ì£¼ì˜ ì‹ ê·œ 보통주를 주당 55.49달러ì—�, 3,990ë§� ê°œì˜ ì›ŒëŸ°íŠ�(행사가 99.88달러ì� 3,600ë§� ì£� 시리ì¦� A 워런íŠ� ë°� 0.0001달러ì� ì„ ì§€ê¸� 워런íŠ� 386ë§� ì£�)ë¥� 혼합하여 발행하는 ë°©ì‹ìž…니ë‹�. ì´� 수ìµì€ 10ì–� 달러ì´ë©°, 2,000ë§� 달러ì� ì¸ìˆ˜ 수수료와 150ë§� 달러ì� 비용ì� 제외í•� 순수ìµì€ 9ì–�7,850ë§� 달러ë¡� 예ìƒë©ë‹ˆë‹�.

ì´ë²ˆ ìžê¸ˆ 조달ë¡� 발행 ì£¼ì‹ ìˆ˜ëŠ” 2ì–�4,310ë§� 주ì—ì„� 즉시 2ì–�8,390ë§� 주로 ì¦ê°€í•˜ë©°(모든 워런트가 행사ë� 경우 3ì–�2,380ë§� ì£�), í¬ì„ë¥ ì€ ì•� 17%(ë˜ëŠ” ì•� 33%)ì—� 달합니다. 투ìžìžë“¤ì€ ì¡°ì •ë� 유형 장부가ì¹� 기준으로 주당 즉시 48.96달러ì� í¬ì„ì� 경험하게 ë©ë‹ˆë‹�(거래 í›� 6.53달러, 제안가 55.49달러 대ë¹�). 제안 ê°€ê²©ì€ 2025ë…� 7ì›� 3ì� 종가 44.39달러보다 ì•� 25% ë†’ì€ ìˆ˜ì¤€ìœ¼ë¡œ, í¬ì„ì—ë„ ë¶ˆêµ¬í•˜ê³  강한 기관 수요ë¥� 나타냅니ë‹�.

ìžê¸ˆ 사용ì²�: ìš´ì „ìžë³¸, 연구개발, 그리ê³� IonQì� ê³ ì¶©ì‹¤ë„ ë°� 대규모 í비íŠ� ì–‘ìž ì‹œìŠ¤í…� 개발 ë¡œë“œë§µì„ ê°€ì†í™”í•� ìˆ� 있는 잠재ì � ì „ëžµì � ì¸ìˆ˜ ë°� 파트너십. J.P. 모건ì� ë‹¨ë… ì¸ìˆ˜ì¸ìœ¼ë¡� 참여하며, 워런트는 거래ì†� ìƒìž¥ì� ë˜ì§€ 않아 단기 유ë™ì„±ì´ 제한ë©ë‹ˆë‹�.

주요 위험 사항으로ëŠ� ì§€ì†ì ì� ì˜ì—… ì†ì‹¤(ëˆ„ì  ì ìž 7ì–�1,600ë§� 달러), ì–‘ìž í•˜ë“œì›¨ì–´ 확장 실행ì� 어려움, 현금 배당 미지ê¸�, 제한ë� 워런íŠ� 유ë™ì„�, ìž„ì› ë§¤ë„ì—� 대í•� 60ì� 잠금 기간ë§� 존재하는 ì � ë“±ì´ í¬í•¨ë©ë‹ˆë‹�.

IonQ (NYSE : IONQ) a lancé une levée de fonds d’un milliard de dollars via une offre mixte comprenant 14,17 millions de nouvelles actions ordinaires à 55,49 dollars et 39,9 millions de bons de souscription (36,0 millions de série A avec un prix d’exercice à 99,88 dollars et 3,86 millions de bons préfinancés à 0,0001 dollar). Le produit brut totalise 1,0 milliard de dollars et le produit net, après 20 millions de dollars de frais de souscription et 1,5 million de dollars de dépenses, est estimé à 978,5 millions de dollars.

Ce financement portera immédiatement le nombre total d’actions en circulation de 243,1 millions à 283,9 millions (323,8 millions si tous les bons sont exercés), ce qui représente une dilution d’environ 17 % (ou environ 33 %). Les acheteurs subiront une dilution immédiate de 48,96 dollars par action sur la valeur comptable tangible ajustée (6,53 dollars après l’opération contre le prix d’offre de 55,49 dollars). Le prix d’offre est environ 25 % supérieur au cours de clôture du 3 juillet 2025, à 44,39 dollars, indiquant une forte demande institutionnelle malgré la dilution.

Utilisation des fonds : fonds de roulement, R&D, et acquisitions/partenariats stratégiques potentiels pouvant accélérer la feuille de route d’IonQ vers des systèmes quantiques à qubits plus nombreux et de meilleure fidélité. J.P. Morgan agit en tant que seul souscripteur ; les bons ne seront pas cotés en bourse, limitant la liquidité à court terme.

Principaux risques divulgués : pertes opérationnelles continues (déficit cumulé de 716 millions de dollars), défis dans la montée en puissance du matériel quantique, absence de dividendes en espèces, liquidité limitée des bons et période de blocage de seulement 60 jours pour les ventes internes.

IonQ (NYSE: IONQ) hat eine Kapitalerhöhung in Höhe von 1,0 Milliarden US-Dollar gestartet durch ein gemischtes Angebot von 14,17 Millionen neuen Stammaktien zu 55,49 US-Dollar und 39,9 Millionen Warrants (36,0 Millionen Serie A mit einem Ausübungspreis von 99,88 US-Dollar und 3,86 Millionen vorfinanzierte Warrants zu 0,0001 US-Dollar). Die Bruttoerlöse betragen 1,0 Milliarden US-Dollar, die Nettoerlöse nach 20,0 Millionen US-Dollar Underwriting-Gebühren und 1,5 Millionen US-Dollar Ausgaben werden auf 978,5 Millionen US-Dollar ²µ±ð²õ³¦³óä³Ù³ú³Ù.

Die Finanzierung erhöht die Gesamtzahl der ausstehenden Aktien sofort von 243,1 Millionen auf 283,9 Millionen (323,8 Millionen bei Ausübung aller Warrants), was einer Verwässerung von etwa 17 % (bzw. etwa 33 %) entspricht. Käufer werden eine sofortige Verwässerung von 48,96 US-Dollar pro Aktie im bereinigten materiellen Buchwert erfahren (6,53 US-Dollar nach der Transaktion gegenüber dem Angebotspreis von 55,49 US-Dollar). Der Angebotspreis liegt etwa 25 % über dem Schlusskurs vom 3. Juli 2025 von 44,39 US-Dollar, was trotz Verwässerung auf eine starke institutionelle Nachfrage hinweist.

Verwendung der Erlöse: Betriebskapital, Forschung & Entwicklung sowie potenzielle strategische Akquisitionen/Partnerschaften, die IonQs Fahrplan zu höherwertigen, größeren Qubit-Quanten-Systemen beschleunigen könnten. J.P. Morgan fungiert als alleiniger Underwriter; die Warrants werden nicht an der Börse gehandelt, was die kurzfristige Liquidität einschränkt.

Wesentliche Risiken umfassen anhaltende operative Verluste (kumuliertes Defizit von 716,0 Millionen US-Dollar), Herausforderungen bei der Skalierung der Quantenhardware, fehlende Bardividenden, begrenzte Liquidität der Warrants sowie nur eine 60-tägige Sperrfrist für Insiderverkäufe.

BAXTER INTERNATIONAL INC false 0000010456 0000010456 2025-07-07 2025-07-07 0000010456 bax:CommonStock1.00PerValueMember 2025-07-07 2025-07-07 0000010456 us-gaap:DeferrableNotesMember 2025-07-07 2025-07-07
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 7, 2025

 

 

Baxter International Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

1-4448   36-0781620
(Commission File Number)   (I.R.S. Employer Identification No.)

 

One Baxter Parkway, Deerfield, Illinois   60015
(Address of principal executive offices)   (Zip Code)

(224) 948-2000

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $1.00 par value   BAX (NYSE)   New York Stock Exchange
1.3% Global Notes due 2029   BAX 29   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

 Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐

 

 
 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Andrew Hider as President and Chief Executive Officer and Director; Transition of Brent Shafer from Interim CEO and Chair to Non-Executive Chair of the Board

On July 7, 2025 (the “Announcement Date”), Baxter International Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed Andrew Hider as President and Chief Executive Officer (“CEO”) of the Company, effective on the earlier of September 3, 2025 or such date as the Company and Mr. Hider agree, subject to Mr. Hider’s compliance with his existing contractual obligations to his current employer (the “Effective Date”). In connection with Mr. Hider’s appointment as CEO, the Board increased the authorized number of directors on the Board to eleven and appointed Mr. Hider to fill the resulting vacancy on the Board, in each case, effective as of the Effective Date.

Mr. Hider does not have any family relationships with any of the Company’s directors or executive officers, there are no arrangements or understandings between Mr. Hider and any other persons pursuant to which he was selected as an officer or director, and there are no transactions between Mr. Hider and the Company that would be required to be reported under Item 404(a) of Regulation S-K.

On July 7, 2025, the Company and Brent Shafer entered into an amendment to the letter agreement, dated February 1, 2025 and previously filed as Exhibit 10.2 to the Company’s Form 8-K filed on February 3, 2025 (the “Shafer Letter Agreement”), to extend the term of the Shafer Letter Agreement to the Effective Date (the “Shafer Amendment”), which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Q2 Form 10-Q”).

As of the Effective Date, Mr. Shafer will cease to serve as Interim CEO of the Company and will transition to serving as the non-executive Chair of the Board. He will also rejoin the Audit Committee and the Nominating, Corporate Governance and Public Policy Committee of the Board as an independent director, effective as of the Effective Date.

The above description of the Shafer Amendment is qualified in its entirety by reference to the terms of the Shafer Amendment, to be attached to the Q2 Form 10-Q and incorporated herein by reference.

Biographical Information of Mr. Hider

Mr. Hider, age 48, is the Chief Executive Officer and a member of the board of directors of ATS Corporation (TSX and NYSE: ATS), roles which he has held since March 2017 and May 2017, respectively. Previously, Mr. Hider served as President and Chief Executive Officer of the Taylor Made Group, LLC from May 2016 to February 2017. Prior to that, Mr. Hider served for ten years at Danaher Corporation, working in roles of increasing responsibility, most recently serving as President of Veeder Root. Mr. Hider began his career with General Electric, serving in a number of areas including manufacturing, project management, procurement and finance. He also currently serves on the board of directors of Tennant Company (NYSE: TNC). Mr. Hider received a BS in Interdisciplinary Engineering and Management and an MBA from Clarkson University.

CEO Offer Letter with Mr. Hider

The Company and Mr. Hider entered into an offer letter (the “CEO Offer Letter”), effective upon approval by the Board on July 7, 2025, establishing the terms of Mr. Hider’s service as CEO, commencing as of the Effective Date. Mr. Hider’s target direct compensation will comprise an annual base salary of $1,350,000, a target annual bonus opportunity under the Company’s Management Incentive Program (the “MICP”) of 150% of his annual base salary (prorated for 2025 as set forth in the CEO Offer Letter), and eligibility to participate in the Company’s long-term incentive program (the “LTI Plan”) with an initial target annual equity grant value of $14,000,000 (the “LTI Target Value”) (prorated for 2025 as set forth in the CEO Offer Letter and to be granted on the Company’s first scheduled off-cycle grant on or following the Effective Date) comprised of 50% performance share units (“PSUs”), 25% restricted stock units (“RSUs”) and 25% stock options.

Mr. Hider will also receive one-time sign-on compensation comprising (i) a supplemental cash payment of $1,000,000 minus applicable taxes payable within 30 days of the Effective Date and subject to clawback upon his resignation (other than for Good Reason as defined in the CEO Offer Letter) within 12 months of the Effective Date (100%


repayment) or between 12 and 24 months following the Effective Date (50% repayment) and (ii) on the Company’s first scheduled off-cycle grant date on or following the Effective Date, a one-time supplemental equity award with a target grant value equal to $4,000,000 (the “Supplemental Equity Award”) in the form of PSUs under the Company’s LTI Plan.

Mr. Hider will also receive a one-time award on the Company’s first scheduled off-cycle grant on or following the Effective Date as compensation for the unvested portion of certain equity awards previously granted by Mr. Hider’s prior employer, comprising (i) RSUs with a target grant value equal to $5,750,000, with one-third of such award scheduled to vest on each of the first three anniversaries of the grant date and (ii) PSUs with a target grant value equal to $2,750,000 (the “Make Whole Award”).

Mr. Hider will be eligible to participate in the Company’s benefit plans to the same extent as provided to other senior executives of the Company, and the Company will provide Mr. Hider with an annual allowance of $150,000 for personal travel expenses. In addition, Mr. Hider will enter into the Company’s Change in Control agreement (the “CIC Agreement”), which will provide that, in connection with a qualifying termination of employment in connection with a change in control, Mr. Hider will be entitled to receive, among other things: (i) a lump sum payment equal to two and a half times his annual base salary and annual target bonus opportunity and (ii) eighteen months of life, accident and health insurance benefits, in each case, subject to his execution and non-revocation of a separation and general release. Mr. Hider will be bound by standard restrictive covenants under the CIC Agreement, including, among other terms, non-competition, non-solicitation and non-disparagement provisions.

Outside the context of the CIC Agreement, if Mr. Hider’s employment is terminated (i) by the Company other than for Cause (as defined in the Company’s Executive Severance Plan) or (ii) by Mr. Hider for Good Reason (as defined in the CEO Offer Letter), the Company will provide Mr. Hider, not more than 60 days following the date his employment terminates with the Company (“Date of Termination”), with: (i) a lump-sum separation payment equal to two times his annual base salary and annual target bonus in effect as of the Date of Termination; (ii) in the event the Date of Termination is on or after February 1 but before the end of the applicable calendar year, a pro rata payment of his annual incentive under the MICP, calculated using the number of days worked in the applicable calendar year, based on actual financial performance of the Company and target individual performance; (iii) with respect to the Supplemental Equity Award and the Make Whole Award: (1) any outstanding and unvested RSUs will immediately vest on the Date of Termination and (2) any PSUs will remain eligible to vest based on actual performance (and if such awards have not been made prior to the Date of Termination, he will receive an equivalent amount based on an assumed grant date of the Company’s first scheduled off-cycle grant on or following the Effective Date and the Company’s standard calculation methodology); and (iv) a lump-sum cash amount equal to the monthly employer cost of applicable group medical, dental or vision coverage multiplied by 18. In exchange for the foregoing benefits, Mr. Hider will continue to be subject to and abide by the applicable restrictive covenants set forth in his CIC Agreement, without regard to whether a change in control has occurred.

The above description of the CEO Offer Letter is qualified in its entirety by reference to the terms of the CEO Offer Letter, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Item 7.01

Regulation FD Disclosure.

A copy of the Company’s press release relating to the announcements described in Item 5.02, dated July 7, 2025, is furnished as Exhibit 99.1 to this Form 8-K.

In accordance with General Instructions B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.
   Description of Exhibits
10.1    Offer Letter, effective as of July 7, 2025, by and between Andrew Hider and the Company
99.1    Press Release, dated July 7, 2025
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    BAXTER INTERNATIONAL INC.
Date: July 7, 2025     By:  

/s/ Ellen K. Bradford

    Name:   Ellen K. Bradford
    Title:   Senior Vice President and Corporate Secretary

FAQ

How much capital will IonQ (IONQ) raise from this 424B5 offering?

IonQ expects $978.5 million in net proceeds after underwriting fees and expenses.

What is the dilution impact of IonQ’s new share issuance?

Shares outstanding rise from 243.1 million to 283.9 million (or 323.8 million if all warrants are exercised), equating to 17-33 % dilution.

What are the exercise terms of the warrants issued by IonQ?

Series A Warrants: one share each, $99.88 strike, 7-year life. Pre-funded Warrants: $0.0001 strike, 7-year life.

How will IonQ use the proceeds from the offering?

Funds will go toward working capital, R&D, general corporate purposes, and possible strategic acquisitions or partnerships.

Will the new warrants trade on the NYSE?

No. The Series A and Pre-funded Warrants will not be listed on any exchange, limiting secondary-market liquidity.
Baxter Intl Inc

NYSE:BAX

BAX Rankings

BAX Latest News

BAX Stock Data

15.54B
511.23M
0.39%
97.79%
4.1%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
United States
DEERFIELD